In 1998, Tatemoto et al. first isolated apelin from bovine stomach extracts. Apelin is an endogenous peptide ligand for the orphan G-protein-coupled angiotensin receptor-like protein J (APJ) receptor. It is widely distributed in various organs such as the lung, kidney, liver, heart, gastrointestinal tract, and adipose tissue, etc. And it was identified as a novel adipocytokine in 2005.
Apelin has many subtypes, including Apelin-36, Apelin-31, Apelin-28, Apelin-19, Apelin-13, and Apelin-12, etc., among which Apelin-36 is the main form of endogenous Apelin. And it exerts extensive functions in the human body, including the control of blood pressure and blood flow, the stimulation of cardiac contractility, the regulation of water and food intake, adipocyte differentiation, the involvement in glucose uptake and participation in the control of glucose blood levels glycemia.
Apelin signaling pathway refers to the way by which apelin binds to its cognate receptor APJ, thereby mediating the occurrence of multiple signaling pathways that involve in many cellular processes.
In the apelin signaling pathway, apelin is activated by its cognate APJ receptor, triggering a diversity of physiological effects such as vasoconstriction and dilation, the control of blood pressure and blood flow, strengthening of cardiac contractility, angiogenesis, and modulation of energy metabolism and fluid homeostasis.
Apelin exerts its physiologic and pathophysiologic functions through the interaction with its receptor APJ, in the autocrine or paracrine pathway.
Apelin and APJ are found to be highly expressed in various peripheral tissues, especially in the blood vessels, indicating that apelin/APJ plays an important role in angiogenesis and vascular formation. Apelin acts on and activates the APJ receptor. Activated APJ combines with Gi protein and PKC, phosphorylation of p70 S6 kinase through the extracellular signal-regulated kinase (ERK) pathway. Apelin/APJ signaling also activates the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, facilitating endothelial cell migration. Active Akt stimulates the phosphorylation of p70 S6 kinase. Both cell events ultimately promote the proliferation of vascular smooth muscle cells. Liu C et al. also confirmed that this signaling pathway inhibits the apoptosis of vascular smooth muscle cells.
The apelin/APJ pathway mediates the opposite effects to the renin-angiotensin system (RAS) in many physiologic and pathophysiologic conditions. Angiotensin II elevates vascular tone and raises blood pressure, whereas apelin acts as a vasodilator and lowers blood pressure. Many studies have demonstrated that intravenous injection of exogenous apelin can cause decreased systolic and diastolic blood pressure. Apelin binds to and activates APJ, stimulating Akt to activate phosphorylation of endothelial nitric oxide synthase (eNOS). The phosphorylation of eNO promotes the release of NO by endothelial cells. NO increases cGMP by activating ornithylacine cyclase in smooth muscle, which further relaxes vascular smooth muscle and lowers blood pressure, leading to vasodilatation.
The apelin signaling pathway also inhibits adipogenesis through the MAPK pathway and suppresses basal lipolysis through AMP-activated protein kinase-dependent enhancement of perilipin expression.
Apelin is involved in the pathogenesis of many diseases such as heart failure, coronary heart disease, diabetes, lung diseases, and cancer.
Studies have shown that apelin levels increase in the early stage of heart failure but disease in the late stage. In patients with type II diabetes, plasma apelin concentrations are increased. In the study of osteoarthritis (OA), apelin was found in the synovial fluid of osteoarthritis. And its concentration was positively correlated with the severity of OA, suggesting that apelin played a certain role in the occurrence or development of OA. It provides a new perspective on OA pathology.
Apelin has been reported to be widely expressed in endothelial cells of tumors of different origins. And apelin has been identified as a tumor endothelial-specific gene through the gene expression profiles comparison between tumor and normal endothelium.
|ACTA2||ACTA2 Antibody||ACTA2 Protein||ACTA2 cDNA||ACTA2 ELISA Kit|
|ADCY1||ADCY1 Antibody||ADCY1 Protein||ADCY1 cDNA||ADCY1 ELISA Kit|
|ADCY10||ADCY10 Antibody||ADCY10 Protein||ADCY10 cDNA||ADCY10 ELISA Kit|
|ADCY2||ADCY2 Antibody||ADCY2 Protein||ADCY2 cDNA||ADCY2 ELISA Kit|
|ADCY3||ADCY3 Antibody||ADCY3 Protein||ADCY3 cDNA||ADCY3 ELISA Kit|
|ADCY4||ADCY4 Antibody||ADCY4 Protein||ADCY4 cDNA||ADCY4 ELISA Kit|
|ADCY5||ADCY5 Antibody||ADCY5 Protein||ADCY5 cDNA||ADCY5 ELISA Kit|
|ADCY6||ADCY6 Antibody||ADCY6 Protein||ADCY6 cDNA||ADCY6 ELISA Kit|
|ADCY7||ADCY7 Antibody||ADCY7 Protein||ADCY7 cDNA||ADCY7 ELISA Kit|
|ADCY8||ADCY8 Antibody||ADCY8 Protein||ADCY8 cDNA||ADCY8 ELISA Kit|
|ADCY9||ADCY9 Antibody||ADCY9 Protein||ADCY9 cDNA||ADCY9 ELISA Kit|
|AGTR1||AGTR1 Antibody||AGTR1 Protein||AGTR1 cDNA||AGTR1 ELISA Kit|
|AKT1||AKT1 Antibody||AKT1 Protein||AKT1 cDNA||AKT1 ELISA Kit|
|AKT2||AKT2 Antibody||AKT2 Protein||AKT2 cDNA||AKT2 ELISA Kit|
|AKT3||AKT3 Antibody||AKT3 Protein||AKT3 cDNA||AKT3 ELISA Kit|
|APLN||APLN Antibody||APLN Protein||APLN cDNA||APLN ELISA Kit|
|APLNR||APLNR Antibody||APLNR Protein||APLNR cDNA||APLNR ELISA Kit|
|BECN1||BECN1 Antibody||BECN1 Protein||BECN1 cDNA||BECN1 ELISA Kit|
|BECN2||BECN2 Antibody||BECN2 Protein||BECN2 cDNA||BECN2 ELISA Kit|
|CALML3||CALML3 Antibody||CALML3 Protein||CALML3 cDNA||CALML3 ELISA Kit|